#United States #Washington D.C. #Implantica #GERD #RefluxStop

Implantica Launches RefluxStop® in the U.S. at AFS 2026

Implantica AG, a trailblazer in medical technology innovations, recently celebrated a pivotal moment during the 2026 American Foregut Society (AFS) Meeting in Washington D.C. The launch of RefluxStop® was met with tremendous enthusiasm from prominent gastroenterologists and surgeons, marking a significant step forward in the treatment of gastroesophageal reflux disease (GERD).

A New Era in GERD Treatment

With RefluxStop® now FDA-approved, the company aims to redefine the standards for GERD treatment in the United States. GERD is a chronic ailment affecting nearly 78 million Americans, and the RefluxStop® provides a groundbreaking alternative to traditional anti-reflux surgical methods. Unlike conventional procedures that wrap around the esophagus, RefluxStop® aims to maintain the body's natural anatomical structure while effectively preventing reflux. This innovative approach offers a safer profile by minimizing common post-surgical complications like swallowing difficulties and loss of belching ability.

During the AFS Annual Meeting, the atmosphere was electric with excitement, culminating in an overflow for the RefluxStop® panel discussion that drew over 120 healthcare professionals. The panel, moderated by Dr. John Lipham, an esteemed leader in upper GI surgery, emphasized the importance of this groundbreaking treatment, declaring it a milestone in the evolution of GERD management. Dr. Lipham remarked, “The FDA PMA approval for RefluxStop represents an inflection point in GERD treatment, supported by five years of clinical outcomes.”

The Engaged Medical Community

The symposium featured several notable guests, including Dr. Christy Dunst, Dr. Peter Kahrilas, and Dr. Tripp Buckley, all prominent figures in foregut medicine. Their collective expertise provided insights into the revolutionary concept behind RefluxStop®, attracting considerable attention from the audience.

Dr. Peter Forsell, founder and CEO of Implantica, was equally enthusiastic about the reception. “It was inspiring to witness the considerable interest from leading U.S. surgeons and gastroenterologists at AFS 2026. The capacity audience underscores the pressing need for innovative GERD treatment solutions,” he stated, highlighting nearly 30 one-on-one meetings held with surgeons eager to adopt this promising technology.

Clinical and Practical Applications

The discussion around RefluxStop® was further fueled by the release of a recently published paper titled “How I do it?,” authored by two of the leading users in Germany and Switzerland, positioning RefluxStop® among the top trending presentations at the meeting.

Given that over 40% of patients in the U.S. report ongoing symptoms despite regular medication, RefluxStop® is primed to fill a significant gap in GERD treatment standards. As a result, Implantica is focusing on a systematic rollout across the United States, collaborating with medical institutions and clinicians to introduce this revolutionary device into practice.

Looking Forward

As Implantica forges ahead, the anticipation surrounding RefluxStop® reaffirms its potential to reshape the landscape of anti-reflux surgery, capitalizing on unmet medical needs. The recent AFS Meeting served not just as a launch pad for RefluxStop® but as a clear indicator of the medical community's growing recognition of innovative approaches to long-standing health issues. With a commitment to improving patient outcomes through advanced technology, Implantica stands at the forefront of changing what patients can expect from GERD treatments, ensuring a future where RefluxStop® is a cornerstone of care for millions.

For further information, contact Nicole Pehrsson at Implantica.

This article is based on information reported by PR Newswire on September 29, 2026.